 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | AVLX-144 / Avilex Pharma
Journal: Development of Peptide-Based Probes for Molecular Imaging of the Postsynaptic Density in the Brain. (Pubmed Central) - Jul 26, 2024
Here, we exploit a high-affinity inhibitor of PSD-95, AVLX-144, as a template for developing probes for molecular imaging of the PSD...Notably, we observed diminished tracer binding in human post-mortem Parkinson's disease (PD) brain slices, suggesting postsynaptic impairment in PD. We thus offer a suite of translational probes for visualizing and understanding PSD-related pathologies.
- || AVLX-144 / Avilex Pharma
Trial completion, Trial completion date, Trial primary completion date: A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 (clinicaltrials.gov) - Jul 20, 2023
P1, N=46, Completed, Sponsor: Avilex Pharma
We thus offer a suite of translational probes for visualizing and understanding PSD-related pathologies. Recruiting --> Completed | Trial completion date: Apr 2021 --> Jul 2023 | Trial primary completion date: Feb 2021 --> Jul 2023
- | AVLX-144 / Avilex Pharma
New P1 trial: A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 (clinicaltrials.gov) - Dec 29, 2020
P1, N=48, Recruiting, Sponsor: Avilex Pharma